Jacob Asset Management of New York LLC Has $1.70 Million Stake in TELA Bio, Inc. (NASDAQ:TELA)

Jacob Asset Management of New York LLC boosted its stake in TELA Bio, Inc. (NASDAQ:TELAGet Rating) by 17.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 133,000 shares of the company’s stock after buying an additional 20,000 shares during the period. Jacob Asset Management of New York LLC’s holdings in TELA Bio were worth $1,702,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Schonfeld Strategic Advisors LLC increased its holdings in TELA Bio by 5.4% in the third quarter. Schonfeld Strategic Advisors LLC now owns 144,353 shares of the company’s stock valued at $1,972,000 after purchasing an additional 7,400 shares during the period. Opaleye Management Inc. increased its holdings in TELA Bio by 0.6% in the third quarter. Opaleye Management Inc. now owns 443,199 shares of the company’s stock valued at $6,054,000 after purchasing an additional 2,734 shares during the period. Granite Point Capital Management L.P. increased its holdings in TELA Bio by 13.8% in the third quarter. Granite Point Capital Management L.P. now owns 227,644 shares of the company’s stock valued at $3,110,000 after purchasing an additional 27,644 shares during the period. Geode Capital Management LLC increased its holdings in TELA Bio by 1.3% in the third quarter. Geode Capital Management LLC now owns 64,923 shares of the company’s stock valued at $886,000 after purchasing an additional 824 shares during the period. Finally, Bank of America Corp DE increased its holdings in TELA Bio by 16.6% in the second quarter. Bank of America Corp DE now owns 7,682 shares of the company’s stock valued at $124,000 after purchasing an additional 1,093 shares during the period.

A number of analysts have weighed in on TELA shares. JMP Securities reiterated a “buy” rating and set a $22.00 price target on shares of TELA Bio in a report on Tuesday, March 22nd. Zacks Investment Research upgraded TELA Bio from a “sell” rating to a “hold” rating in a report on Tuesday, April 12th.

TELA Bio stock traded down $0.14 during trading hours on Thursday, reaching $9.46. 484 shares of the company’s stock were exchanged, compared to its average volume of 15,089. The company has a quick ratio of 4.86, a current ratio of 5.58 and a debt-to-equity ratio of 1.57. The firm’s 50 day simple moving average is $11.17 and its 200 day simple moving average is $11.96. TELA Bio, Inc. has a twelve month low of $8.82 and a twelve month high of $16.53. The firm has a market capitalization of $137.64 million, a PE ratio of -4.19 and a beta of 1.57.

TELA Bio (NASDAQ:TELAGet Rating) last issued its quarterly earnings results on Monday, March 21st. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.05). TELA Bio had a negative return on equity of 106.93% and a negative net margin of 112.94%. The business had revenue of $8.37 million for the quarter, compared to analyst estimates of $7.90 million. During the same quarter in the previous year, the business posted ($0.54) earnings per share. Analysts anticipate that TELA Bio, Inc. will post -1.86 EPS for the current year.

In related news, insider Ew Healthcare Partners Fund 2, acquired 2,520 shares of the business’s stock in a transaction dated Friday, February 18th. The shares were bought at an average price of $11.75 per share, with a total value of $29,610.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders have bought a total of 67,282 shares of company stock worth $716,596 in the last three months. Insiders own 15.90% of the company’s stock.

TELA Bio Company Profile (Get Rating)

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.

Featured Stories

Want to see what other hedge funds are holding TELA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TELA Bio, Inc. (NASDAQ:TELAGet Rating).

Institutional Ownership by Quarter for TELA Bio (NASDAQ:TELA)

Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.